Skip to content

24/7 dementia helpline 800-272-3900

Dementia Today

Untangling the mysteries of Alzheimer’s

Dementia TodayPublished February 2, 20123 min read

Key points

  • One of the most distinctive signs of the development of Alzheimer’s disease is a change in the behavior of a protein that neuroscientists call tau.
  • “What we discovered is that there are smaller structures that form before the neurofibrillary tangles, and they are much more toxic than the big structures,” said Rakez Kayed, UTMB assistant professor and senior author of a paper on the work now online in the FASEB Journal.
  • “One thing that’s remarkable about this research is that before we developed this antibody, people couldn’t even see tau oligomers in the brain,” Kayed said.
  • Other experiments revealed specific biochemical behavior and structures taken on by oligomers, and demonstrated their presence outside neurons — in particular, on the walls of blood vessels.

One of the most distinctive signs of the development of Alzheimer’s disease is a change in the behavior of a protein that neuroscientists call tau. In normal brains, tau is present in individual units essential to neuron health. In the cells of Alzheimer’s brains, by contrast, tau proteins aggregate into twisted structures known as “neurofibrillary tangles.” These tangles are considered a hallmark of the disease, but their precise role in Alzheimer’s pathology has long been a point of contention among researchers.

Now, University of Texas Medical Branch at Galveston researchers have found new evidence that confirms the significance of tau to Alzheimer’s. Instead of focusing on tangles, however, their work highlights the intermediary steps between a single tau protein unit and a neurofibrillary tangle – assemblages of two, three, four, or more tau proteins known as “oligomers,” which they believe are the most toxic entities in Alzheimer’s.

“What we discovered is that there are smaller structures that form before the neurofibrillary tangles, and they are much more toxic than the big structures,” said Rakez Kayed, UTMB assistant professor and senior author of a paper on the work now online in the FASEB Journal. “And we established that they were toxic in real human brains, which is important to developing an effective therapy.”

According to Kayed, a key antibody developed at UTMB called T22 enabled the team to produce a detailed portrait of tau oligomer behavior in human brain tissue. Specifically designed to bond only to tau oligomers (and not lone tau proteins or neurofibrillary tangles), the antibody made it possible for the researchers to use a variety of analytical tools to compare samples of Alzheimer’s brain with samples of age-matched healthy brain.

“One thing that’s remarkable about this research is that before we developed this antibody, people couldn’t even see tau oligomers in the brain,” Kayed said. “With T22, we were able to thoroughly characterize them, and also study them in human brain cells.”

Among the researchers’ most striking findings: in some of the Alzheimer’s brains they examined, tau oligomer levels were as much as four times as high as those found in age-matched control brains.

Other experiments revealed specific biochemical behavior and structures taken on by oligomers, and demonstrated their presence outside neurons — in particular, on the walls of blood vessels.

“We think this is going to make a big impact scientifically, because it opens up a lot of new areas to study,” Kayed said. “It also relates to our main focus, developing a cure for Alzheimer’s. And I find that very, very exciting.”
###

Other authors of the paper include postdoctoral fellows Cristian Lasagna-Reeves, Diana Castillo-Carranza and Jose Sarmiento, research associate Urmi Sengupta, Dr. Juan Troncoso of Johns Hopkins University School of Medicine, and Dr. George Jackson, director of UTMB’s Mitchell Center for Neurodegenerative Diseases. Support for this work was provided by the Cullen Family Trust for Health Care, the Alzheimer’s Drug Discovery Foundation and the George and Cynthia Mitchell Center for Neurodegenerative Diseases.

###

Jim Kelly
jpkelly@utmb.edu
409-772-8791
University of Texas Medical Branch at Galveston

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. If a person with dementia is missing, injured or in danger, call 911 or your local emergency number.

Filed underDementia News

Worried about memory changes?

Normal aging, or an early warning sign?

Ten common changes, each set beside what is typical with age. Tick what you have noticed and see what to do next.

Open the 10-sign checklist

Getting help

Sudden changes are not just the dementia.

Dementia usually changes slowly. A sharp change over hours or days can mean an infection, delirium, a stroke or a medication problem, and needs a doctor the same day. Call 911 or your local emergency number if you see any of these:

  • Confusion that comes on suddenly, over hours or days
  • Face drooping, arm weakness or slurred speech
  • A fall, a head injury or new severe pain
  • Very drowsy or hard to wake

The free Alzheimer’s Association Helpline answers questions about memory loss, diagnosis and caregiving, day and night, in more than 200 languages (US).

If someone with dementia is missing

  1. STEP 115 minSearch close by firstCheck the house, garden, car and the places the person often walks to. Don’t spend longer than about 15 minutes.
  2. STEP 2911Then call for helpTell the operator the person has dementia and is a vulnerable adult. Police treat this as urgent.
  3. STEP 3PhotoHave details readyA recent photo, what they were wearing, medical conditions and places they used to live or work.

Based on Alzheimer’s Association guidance on wandering. Outside the US, call your local emergency number.